Free tool
FAERS Monitor: Penpulimab-Kcqx
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761258 or its brand name (Penpulimab-Kcqx, Penpulimab-Kcqx). Reports on generic versions are filed under their own applications.
Reports
98
Serious
98
100% of reports
Hospitalization
43
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaemia13
- myelosuppression13
- rash11
- hypothyroidism10
- leukopenia10
- nausea10
- thrombocytopenia10
- anaphylactic shock9
- diarrhoea9
- hepatic function abnormal9
- chest discomfort8
- vomiting8
- pruritus7
- pyrexia7
- alanine aminotransferase increased6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 9 |
| 2025 | 12 |
| 2026 | 63 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,061 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 13 | 77.5 | 46.7 | 908 |
| anaphylactic shockSignal | 9 | 75.0 | 40.2 | 585 |
| hypothyroidismSignal | 10 | 67.2 | 37.4 | 589 |
| hepatic function abnormalSignal | 9 | 51.8 | 27.8 | 399 |
| leukopeniaSignal | 10 | 42.9 | 23.9 | 369 |
| alanine aminotransferase increasedSignal | 6 | 21.0 | 9.7 | 95 |
| thrombocytopeniaSignal | 10 | 19.2 | 10.7 | 156 |
| chest discomfortSignal | 8 | 16.8 | 8.6 | 104 |
| anaemiaSignal | 13 | 14.6 | 8.8 | 153 |
| rashSignal | 11 | 5.4 | 3.1 | 36 |
| pyrexiaSignal | 7 | 4.3 | 2.1 | 15 |
| pruritusSignal | 7 | 3.9 | 1.9 | 13 |
| vomitingSignal | 8 | 3.7 | 1.9 | 13 |
| diarrhoeaSignal | 9 | 3.0 | 1.6 | 10 |
| nauseaSignal | 10 | 2.7 | 1.5 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.